Physicians who are part of value-based care delivery models believe the pharmaceutical industry can play a larger role in accountable care organizations and other value-based models, according to a survey conducted by Oliver Wyman.
Out of the survey's 200 physician respondents, 61 percent agreed or strongly agreed that branded drug therapies have a role in reducing the cost of patient care when used appropriately.
"Drug spend is not considered today in most contracts between ACOs and payors," Mark Mozeson, a partner at Oliver Wyman and survey co-director, said in a news release. "Many in the industry expect that to change in the near future. And as it does, drug makers will have the opportunity in many cases to move away from negotiating unit price with commercial health plans and instead contract directly with providers based on outcomes and ability to manage total disease costs. Their ability to demonstrate value will determine whether they have a seat at the table."
Methodist Health System's Approach to PCMHs and ACOs: Q&A With Dr. Melissa Gerdes
12 ACOs Form Statewide Association in Florida
Out of the survey's 200 physician respondents, 61 percent agreed or strongly agreed that branded drug therapies have a role in reducing the cost of patient care when used appropriately.
"Drug spend is not considered today in most contracts between ACOs and payors," Mark Mozeson, a partner at Oliver Wyman and survey co-director, said in a news release. "Many in the industry expect that to change in the near future. And as it does, drug makers will have the opportunity in many cases to move away from negotiating unit price with commercial health plans and instead contract directly with providers based on outcomes and ability to manage total disease costs. Their ability to demonstrate value will determine whether they have a seat at the table."
More Articles on ACOs:
5 Challenges to the Spread of ACOsMethodist Health System's Approach to PCMHs and ACOs: Q&A With Dr. Melissa Gerdes
12 ACOs Form Statewide Association in Florida